Physiological role of endothelin in cardiovascular and renal hemodynamics: Studies in animals

Current Opinion in Nephrology and Hypertension

Volumn 6, Issue 1, 1997, Pages 64-68

  Gellai, Miklos ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN;

HEART HEMODYNAMICS; KIDNEY BLOOD FLOW; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; CARDIOVASCULAR PHYSIOLOGY; ENDOTHELINS; RECEPTORS, ENDOTHELIN; RENAL CIRCULATION;

EID: 0031039192     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-199701000-00012     Document Type: Review

References (50)

1. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature (Lond) 1988, 332:411-415.
2. Haynes WG, Webb DJ: The endothelin family of peptides: local hormones with diverse roles in health and disease? Clin Sci 1993, 84:485-500.
3. Yokokawa K, Johnson J, Kohno M, Mandal AK, Yanagisawa M, Horio T, Yasunari K, Takeda T: Phosphoinositide turnover signaling stimulated by ET-3 in endothelial cells from spontaneously hypertensive rats. Am J Physiol 1994, 267:R635-R644.
4. Schiffrin EL: Endothelin: potential role in hypertension and vascular hypertrophy. Hypertension 1995, 25:1135-1143.
5. Haynes WG: Endothelins as regulators of vascular tone in man. Clin Sci 1995, 88:509-517.
6. Gellai M, Jugus M, Fletcher T, Nambi P, Ohlstein EH, Elliott JD, Brooks DP: Nonpeptide endothelin receptor antagonists. V: prevention and reversal of acute renal failure in the rat by SB 209670. J Pharmacol Exp Ther 1995, 275:200-206.
7. Kloog Y, Ambar I, Sokolovsky M, Wolleberg Z: Sarafotoxin, a novel vasoconstrictor peptide: phosphoinositide hydrolysis in rat heart and brain. Science 1989, 242:268-270.
8. Arai H, Hori S, Aramori I, Ohkubo H, Nakanish S: Cloning and expression of a cDNA encoding an endothelin receptor. Nature (Lond) 1990, 348:730-732.
9. Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K, Masaki TE: Cloning of a cDNA encoding a nonisopeptide-selective subtype of an endothelin receptor. Nature (Lond) 1990, 348:732-735.
10. Brooks DP, Depalma PD, Pullen M, Nambi P: Characterization of canine renal endothelin receptor subtypes and their function. J Pharmacol Exp Ther 1994, 268:1091-1097.
11. Tschudi MR, Lüscher TF: Characterization of contractile endothelin and angiotensin receptors in human resistance arteries: evidence for two endothelin and one angiotensin receptor. Biochem Biophys Res Commun 1994, 204:685-690.
12. Gardiner SM, Kemp PA, March JE, Bennett T, Davenport AP, Edvinsson L: Effects of an ET1-receptor antagonist, FR139317, on regional haemodynamic responses to endothelin-1 and [Ala11,15]Ac-endothelin-1 (6-21) in conscious rats. Br J Pharmacol 1994, 112:477-486.
13. Gellai M, DeWolf R, Pullen M, Nambi P: Distribution and functional role of renal ET receptor subtypes in normotensive and hypertensive rats. Kidney Int 1994, 46:1287-1294.
14. Denucci G, Thomas R, D'Orleans-Juste P, Antunes E, Walder C, Warner TD, Vane JR: Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci U S A 1988, 85:9797-9800.
15. B-receptor-selective agonist BQ3020, in conscious rats [Abstract]. Br J Pharmacol 1993, 109:131P.
16. Tanaka T, Tsukuda E, Nozawa M, Nonaka H, Ohno T, Kase H, Yamada A K, Matsuda Y: RES-701-1, a novel potent endothelin type B receptor-selective antagonist of microbial origin. Mol Pharmacol 1994, 45:724-730.
17. B-selective agonist displays species differences in its binding characteristics. Neuropeptides 1995, 28:191-196.
18. Douglas SA, Beck GR Jr, Elliott JD, Ohlstein EH: Pharmacologic evidence for the presence of three functional endothelin receptor subtypes in rabbit saphenous vein. J Cardiovasc Pharmacol 1996, 26(suppl 3):S163-S168.
19. Nishiyama M, Moroi K, Shan LH, Yamamoto M, Takasaki C, Masaki T, Kimura S: Two different endothelin B receptor subtypes mediate contraction of the rabbit saphenous vein. Jpn J Pharmacol 1995, 68:235-243.
20. Douglas SA, Beck GR Jr, Elliott JD, Ohlstein EH: Pharmacological evidence for the presence of three distinct functional endothelin receptor subtypes in the rabbit lateral saphenous vein. Br J Pharmacol 1995, 114:1529-1540.
21. Masaki T, Yanagisawa M: Physiology and pharmacology of endothelins. Med Res Rev 1992, 12:391-421.
22. Gardiner SM, March JE, Kemp PA, Mullins JJ, Bennett T: Haemodynamic effects of losartan and the endothelin antagonist, SB 209670, in conscious, transgenic ((mRen-2)27), hypertensive rats. Br J Pharmacol 1995, 116:2237-2244.
23. Kato T, Kassab S, Wilkins FC Jr, Kirchner KA, Keiser J, Granger JP: Endothelin antagonists improve renal function in spontaneously hypertensive rats. Hypertension 1995, 25:883-887.
24. Donckier J, Stoleru L, Hayashida W, van Mechelen H, Selvais P, Galanti L, Clozel JP, Ketelslegers JM, Pouleur H: Role of endogenous endothelin-1 in experimental renal hypertension in dogs. Circulation 1995, 92:106-113.
25. Teerlink JR, Carteaux JP, Sprecher U, Loffler BM, Clozel M, Clozel JP: Role of endogenous endothelin in normal hemodynamic status of anesthetized dogs. Am J Physiol 1995, 268:H432-H440.
26. Qiu C, Samsell L, Baylis C: Actions of endogenous endothelin on glomerular hemodynamics in the rat. Am J Physiol 1995, 269:R469-R473.
27. B receptor antagonist Ro 46-8443. FEBS Lett 1996, 383:42-45.
28. McMahon EG, Palomo MA, Moore WM: Phosphoramidon blocks the pressor activity of big endothelin [1-39] and lowers blood pressure in spontaneously hypertensive rats. Cardiovasc Pharmacol 1991, 17:S29-S33.
29. Kurihara Y, Kurihara H, Suzuki H, Kodama T, Maemura K, Nagai R, Oda H, Kuwaki T, Cao W, Kamada N et al.: Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature 1994, 368:703-710.
30. Vanhoutte PM: A matter of life and breath. Nature 1994, 368:693-694.
31. Gellai M, Fletcher T, Pullen M, Nambi P: Evidence for the existence of endothelin-B receptor subtypes and their physiological roles in the rat. Am J Physiol 1996, 271:R254-R261. Evidence is provided in support for the role of endogenous ET in the control of basal vascular tone.
32. Gellai M, DeWolf R, Fletcher T, Nambi P: Physiological roles of endothelin (ET) receptor subtypes in the rat. J Am Soc Nephrol 1995, 6:658.
33. Qiu C, Engels K, Baylis C: Endothelin modulates the pressor actions of acute systemic nitric oxide blockade. J Am Soc Nephrol 1995, 6:1476-1481. The results presented by the authors indicate that ET mediates vasoconstric-tion resulting from NO inhibition, at least in the systemic vascular bed.
34. Richard V, Hogie M, Clozel M, Loffler BM, Thuillez C: Demonstration of a vasopressor role of endogenous endothelin after inhibition of nitric oxide synthesis in rats [in French]. Arch Mal Coeur Vaiss 1995, 88:1213-1216.
35. Richard V, Hogie M, Clozel M, Loffler BM, Thuillez C: In vivo evidence of an endothelin-induced vasopressor tone after inhibition of nitric oxide synthesis in rats. Circulation 1995, 91:771-775.
36. Loesch A, Burnstock G: Ultrastructural localization of nitric oxide synthase and endothelin in rat pulmonary artery and vein during postnatal development and ageing. Cell Tissue Res 1996, 283:355-365.
37. Loesch A, Burnstock G: Ultrastructural localization of nitric oxide synthase and endothelin in coronary and pulmonary arteries of newborn rats. Cell Tissue Res 1995, 279:475-483.
38. Harata Y, Emori T, Eguchi S, Kanno K, Imai T, Ohta K, Marumo F: Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J Clin Invest 1993, 91:1367-1373.
39. +-ATPaSe activity by endothelin in rabbit aorta. Am J Physiol 1994, 266:H577-582.
40. Ercan ZS, Turker RK, Uluoglu C, Yazar O, Zengil H: The effects of endothelin peptides in the rabbit isolated perfused kidney. Gen Pharmacol 1994, 25:1471-1476.
41. Hirata Y, Hayakawa H, Suzuki E, Kimura K, Kikuchi K, Nagano T, Hirobe M, Omata M: Direct measurements of endothelium-derived nitric oxide release by stimulation of endothelin receptors in rat kidney and its alteration in salt-induced hypertension. Circulation 1995, 91:1229-1235.
42. Redmond EM, Cahill PA, Hodges R, Zhang S, Sitzmann JV: Regulation of endothelin receptors by nitric oxide in cultured rat vascular smooth muscle cells. J Cell Physiol 1996, 166:469-479.
43. Hinson JP, Kapas S, Cameron LA: Differential effects of endogenous and exogenous nitric oxide on the release of endothelin-1 from the intact perfused rat adrenal gland in situ. FEBS Lett 1996, 379:7-10.
44. Ran P, Xu J, Chen S: Expression of endothelin-1 mRNA, endothelin receptor-A and nitric oxide synthese mRNA in pulmonary artery and right ventriculus cordis of rats exposed to hypoxia. Chung Hua I Hsueh Tsa Chih 1995, 75:479-81.
45. Kohan DE, Padilla E: Endothelin-1 production by rat inner medullary collecting duct: effect of nitric oxide, cGMP, and immune cytokines. Am J Physiol 1994, 266:F291-F297.
46. Kourembanas S, McQuillan LP, Leung GK, Faller DV: Nitric oxide regulates the expression of vasoconstrictors and growth factors by vascular endothelium under both normoxia and hypoxia. J Clin Invest 1993, 92:99-104.
47. Boulanger C, Lüscher TF: Release of endothelin from the porcine aorta. J Clin Invest 1990, 85:587-590.
48. Yokokawa K, Kohno M, Yasunari K, Murakawa K, Takeda T: Endothelin-3 regulates endothelin-1 production in cultured human endothelial cells. Hypertension 1991, 18:304-315.
49. Lerman A, Sandok EK, Hildebrand FL Jr, Burnett JC Jr: Inhibition of endothelium-derived relaxing factor enhances endothelin-mediated vasoconstriction. Circulation 1992, 85:1894-1898.
50. Loffler B, Breu V, Clozel M: Effect of different endothelin receptor antagonists and of the novel non-peptide antagonist Ro 46-2005 on endothelin levels in rat plasma. FEBS Lett 1993, 333:108-110.